This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Continuity Biosciences starts...
Tech clinical trial

Continuity Biosciences starts pancreatic cancer trial

Analysis based on 6 articles · First reported May 20, 2026 · Last updated May 20, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The initiation of a Phase I clinical trial by Continuity Biosciences for its precision drug delivery platform in pancreatic cancer could positively impact the biotechnology and pharmaceutical sectors. Success in this trial may lead to enhanced treatment options for pancreatic cancer, potentially increasing the market value and investment appeal of Continuity Biosciences and similar companies focused on oncology innovations.

Biotechnology Pharmaceuticals Healthcare
Event Summary

Continuity Biosciences, a clinical-stage biotechnology company, announced the initiation of a Phase I, first-in-human clinical trial for its iontophoretic oncology platform (IOP) to treat pancreatic cancer. The trial, evaluating gemcitabine delivered via IOP, is now open for enrollment at academic medical centers including WVU Medicine J.W. Ruby Memorial Hospital and A. Alfred Taubman Health Care Center. The IOP platform aims to deliver therapeutics directly into pancreatic tumors, increasing drug concentration while minimizing systemic toxicity, thereby enhancing the effectiveness of existing and emerging oncology therapies. This development is significant given pancreatic cancer's high mortality rate and the challenges in effective drug delivery.

Entities Involved
priv
Continuity Biosciences
Continuity Biosciences initiated a Phase I clinical trial for its iontophoretic oncology platform (IOP) to treat pancreatic cancer, which could significantly advance its drug delivery technology and potential market value.
Importance 100.0 Sentiment 70.0
per
Ramakrishna Venugopalan
As CEO of Continuity Biosciences, Ramakrishna Venugopalan announced the initiation of the clinical trial, highlighting the company's mission to transform solid tumor therapy delivery.
Importance 70.0 Sentiment 60.0
oth
WVU Medicine J.W. Ruby Memorial Hospital
WVU Medicine J.W. Ruby Memorial Hospital is one of the academic medical centers where the clinical trial is open for enrollment, contributing to the study's execution.
Importance 30.0 Sentiment 20.0
oth
West Virginia University
West Virginia University's academic medical center, WVU Medicine J.W. Ruby Memorial Hospital, is participating in the clinical trial.
Importance 30.0 Sentiment 20.0
oth
A. Alfred Taubman Health Care Center
A. Alfred Taubman Health Care Center, part of the University of Michigan, is another academic medical center enrolling patients for the clinical trial.
Importance 30.0 Sentiment 20.0
per
Jen Jen Yeh
Jen Jen Yeh, Director of the Pancreatic Cancer Center of Excellence at the University of North Carolina Lineberger Comprehensive Cancer Center, provided expert commentary on the urgent need for better pancreatic cancer treatments.
Importance 20.0 Sentiment 20.0
oth
University of North Carolina Lineberger Comprehensive Cancer Center
The University of North Carolina Lineberger Comprehensive Cancer Center's director, Jen Jen Yeh, commented on the importance of new treatment approaches for pancreatic cancer.
Importance 20.0 Sentiment 20.0
per
Brian Boone
Brian Boone, a surgical oncologist at the WVU Cancer Institute, is a principal investigator for the WVU Medicine trial, emphasizing the trial's potential for safer and more effective gemcitabine delivery.
Importance 20.0 Sentiment 20.0
oth
WVU Cancer Institute
The WVU Cancer Institute's surgical oncologist, Brian Boone, is a principal investigator for the clinical trial.
Importance 20.0 Sentiment 20.0
per
Benjamin Ferguson
Benjamin Ferguson, a clinical assistant professor of surgery and surgical oncologist at the University of Michigan Medicine, highlighted the challenge of drug delivery in pancreatic cancer and the trial's potential to overcome it.
Importance 20.0 Sentiment 20.0
oth
University of Michigan Medicine
The University of Michigan Medicine's surgical oncologist, Benjamin Ferguson, commented on the trial's potential to improve pancreatic cancer treatment.
Importance 20.0 Sentiment 20.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.